News

Today, Atomo Diagnostics announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA).  It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator. Addressing the media following the announcement, Founder and CEO of Atomo Diagnostics,...

Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The self-tests, which use the innovative AtomoRapid platform, will allow individuals to confidently screen themselves...

Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at...

Atomo Diagnostics' CEO John Kelly announced today that the Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. The company is now actively engaging with commercialisation and distribution partners to make the test widely available in European and other global markets during 2018...

Delighted to welcome new investors for 2017, earlier this month Atomo Diagnostics announced backing from Grand Challenges Canada (GCC). Investment from the Canadian Government-funded agency totalling US$1 million (A$1.31 million, C$1.32 million), in recognition of a ‘bold idea with big impact in global health’, will help...

In the past 12 months Atomo has secured grant funding to commercialise various tests using its technology, including a grant from the NSW Medical Devices Fund for a digital HIV Self-Test and a grant from the Australian Commonwealth for a range of tropical fever tests. Today...

Atomo is delighted to announce that the company has secured  $1.38 million in grant funding from the Australian Government to assist in the development and commercialisation of new rapid tests for the detection of dengue and chikungunya viruses. Half the world’s population live in areas at risk...

Atomo’s CEO describes the company’s innovations in rapid diagnostics on Sky News Atomo Group CEO, John Kelly, was invited to talk with Peter Switzer on Sky News on 25 July 2016 to discuss the company’s continuing success in the diagnostic technology sector. Atomo has attracted high-profile support...

Atomo Diagnostics is delighted to have received the ‘Innovation in Export’ Award at the 2015 Premier’s NSW Export Awards, hosted by the Export Council of Australia. The award recognises a NSW company that has made innovation an integral part of their exporting process. Atomo currently exports...